Possible scenario
Regulatory Scrutiny Slows
24% Chance
Regulators examine whether OpenAI's entry into life sciences raises issues around patient data, model validation, biosecurity, and concentration of AI infrastructure. The acquisition is unlikely to be blocked outright, but additional conditions could slow commercialization.
Secondary impacts
- Healthcare -0.6%
- Technology -0.4%
Tickers
- OBIO+8.9%
- RXRX-0.9%
- TEM-0.6%
- MSFT-0.2%
Portfolio impact
S&P 500-0.2%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.